

Paracetamol (acetaminophen)



Essential medicine status ✓

Section: 5. Medicines for neurological disorders > 5.1. Medicines for central nervous system disorders > 5.1.5. Medicines for headache disorders > 5.1.5.1. Medicines for acute migraine attacks

EMLc

ATC codes: N02BE01

| | | |
|--------------------------|---|--------------------|
| Indication | Migraine | ICD11 code: 8A80.Z |
| INN | Paracetamol | |
| Medicine type | Chemical agent | |
| List type | Core (EML) (EMLc) | |
| Additional notes | *The presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided | |
| Formulations | Oral > Liquid: 125 mg per 5 mL (EMLc) ; 120 mg per 5 mL (EMLc) ; 250 mg per 5 mL (EMLc) Local > Rectal > Suppository: 250 mg (EMLc) Oral > Solid > dispersible tablet: 100 mg (EMLc) ; 250 mg (EMLc) Oral > Solid > tablet: 250 mg ; 325 mg ; 500 mg | |
| EML status history | First added in 1987 (TRS 770) Changed in 2007 (TRS 950) Changed in 2017 (TRS 1006) Changed in 2023 (TRS 1049) | |
| Sex | All | |
| Age | Also recommended for children | |
| Therapeutic alternatives | The recommendation is for this specific medicine | |
| Patent information | Patents have expired in most jurisdictions Read more about patents . | |
| Wikipedia | Paracetamol (acetaminophen) | |
| DrugBank | Paracetamol (Acetaminophen) | |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of the 100 mg tablet formulation from the EML and EMLc - strengths of paracetamol tablets should be specified rather than given in a range - the addition of a 250 mg strength suppository formulation to the EMLc - the addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc - the addition of 250 mg/5mL strength oral liquid formulation to the EMLc - the addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"

